These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 7259691)

  • 1. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1981 Jun; 52(6):337-9. PubMed ID: 7259691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of experimental motion sickness by scopolamine absorbed through the skin.
    Graybiel A; Knepton J; Shaw J
    Aviat Space Environ Med; 1976 Oct; 47(10):1096-100. PubMed ID: 791234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1982 Aug; 53(8):770-2. PubMed ID: 7181807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study.
    Laitinen LA; Tokola O; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1981 Jan; 52(1):6-10. PubMed ID: 7011299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
    Noy S; Shapira S; Zilbiger A; Ribak J
    Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human assay of antimotion sickness drugs.
    Graybiel A; Wood CD; Knepton J; Hoche JP; Perkins GF
    Aviat Space Environ Med; 1975 Sep; 46(9):1107-18. PubMed ID: 1100039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chlorpheniramine and ephedrine in combination for motion sickness.
    Buckey JC; Alvarenga DL; MacKenzie TA
    J Vestib Res; 2007; 17(5-6):301-11. PubMed ID: 18626140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of double-dose transdermal scopolamine.
    Bar R; Gil A; Tal D
    Pharmacotherapy; 2009 Sep; 29(9):1082-8. PubMed ID: 19698013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
    Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of transdermally administered scopolamine in preventing motion sickness.
    McCauley ME; Royal JW; Shaw JE; Schmitt LG
    Aviat Space Environ Med; 1979 Nov; 50(11):1108-11. PubMed ID: 393242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of antimotion sickness medications on the secondary symptoms of motion sickness.
    Wood CD; Stewart JJ; Wood MJ; Manno JE; Manno BR; Mims ME
    Aviat Space Environ Med; 1990 Feb; 61(2):157-61. PubMed ID: 2178599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of the effectiveness of drugs for prevention of motion sickness].
    Galle RR; Gusakova GA; Sabaev VV; Galle NN
    Kosm Biol Aviakosm Med; 1988; 22(4):90-4. PubMed ID: 3066982
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea.
    Attias J; Gordon C; Ribak J; Binah O; Rolnick A
    Aviat Space Environ Med; 1987 Jan; 58(1):60-2. PubMed ID: 3814034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
    Homick JL; Kohl RL; Reschke MF; Degioanni J; Cintron-Trevino NM
    Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of motion sickness in parabolic flight with buccal scopolamine.
    Norfleet WT; Degioanni JJ; Calkins DS; Reschke MF; Bungo MW; Kutyna FA; Homick JL
    Aviat Space Environ Med; 1992 Jan; 63(1):46-51. PubMed ID: 1550533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Redetzki HM
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A262-5. PubMed ID: 3675502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological interventions for motion sickness: cardiovascular effects.
    Sunahara FA; Farewell J; Mintz L; Johnson WH
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A270-6. PubMed ID: 3499896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of scopolamine and cyclizine on visual-vestibular interaction in humans.
    Gowans J; Matheson A; Darlington CL; Smith PF
    J Vestib Res; 2000; 10(2):87-92. PubMed ID: 10939683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.
    Parrott AC
    Aviat Space Environ Med; 1989 Jan; 60(1):1-9. PubMed ID: 2647072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of anti-motion sickness drugs in the squirrel monkey.
    Cheung BS; Money KE; Kohl RL; Kinter LB
    J Clin Pharmacol; 1992 Feb; 32(2):163-75. PubMed ID: 1613127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.